Bristol Myers Squibb and 2seventy bio’s Abecma gets positive FDA committee vote for multiple myeloma
In a significant development in the healthcare industry, Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) have announced a favorable vote by the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) regarding Abecma (idecabtagene vicleucel). The committee’s 8-3 vote supports the therapy’s benefit/risk profile for patients with triple-class exposed […]